Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
LONDON – T-knife Therapeutics GmbH closed a $110 million series B, as it advances plans for the phase I/II trial of its first fully human T-cell receptor (TCR) in the treatment of solid tumors, which is due to start later this year.
Biopharmas raising money in public or private financings, including: Adagio, Aridis, Bionomics, Cerecor, Cymabay, Eliem, Evotec, Immunovant and Roivant.
PERTH, Australia – Soft tissue regeneration company Aroa Biosurgery Ltd. completed a A$47 million (US$34.72 million) placement on the Australian Securities Exchange that will allow the company to accelerate and broaden its pipeline. What sets Auckland, New Zealand-based Aroa apart from other regenerative tissue companies is the rate of tissue regeneration with Aroa’s scaffold and its affordability, Aroa founder and CEO Brian Ward told BioWorld.
PARIS – Peek Health SA raised $3.5 million in series A funding to ramp development of its 3D pre-op digital planning tools used in orthopedic surgery. This investment was led by two Portuguese venture capital firms: Grosvenor House of Investments SCR SA and Portugal Ventures SA.
LONDON – Topas Therapeutics GmbH announced the close of a series B round at €40 million (US$47.5 million), to take forward its two lead immune tolerizing programs. The first, TPM-203, is in clinical development for the treatment of the rare, severe autoimmune skin disorder pemphigus vulgaris, while the second, TPM-502, is due to enter the clinic in celiac disease before the end of the year.
RSS
